Prof. A. De Wever SAFETY, EFFICACY, QUALITY AND RISK/BENFIT RATIO Source : Marc Czarka.

Slides:

Advertisements

Similar presentations

EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.

Advertisements

Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958 (FFDCA)

The United States Federal Food, Drug, and Cosmetic Act (FFDCA)

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

RMP: DEFINITIONS AND REGULATORY ASPECTS Marc Czarka, MD, FBCPM Managing Partner HM3A ( Market Autorisation and Access Associates )

Government Agencies HUM-FNW-3 Unit 4. USDA United States Department of Agriculture Mission Statement We provide leadership on food, agriculture, natural.

I&EHL: EU Pharmaceutical Law André den Exter

ICH GCP, the MHRA and PATHOLOGY PATHOLOGY QUALITY ASSURANCE Rob Wosley MRQA SEPTEMBER 2009.

Introduction to Regulation

Bibliographic Instruction Presentation (LIS 5916) U.S. Food and Drug Administration (FDA) By George Nichols (June 2005)

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

EMERGING AND RE-EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA - AVIESAN Workshop June 19th 2012, European Parliament, Bruxelles.

-Drafted in Amendment Years were in 1954 and National law in United States.

Good Clinical Practice GCP

The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.

1 The European Paediatric Initiative Agnès Saint Raymond, MD Scientific Advice and Orphan Drugs The European Medicines Evaluation Agency.

Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.

EFSA MANAGEMENT PLAN 2008 The Management Plan

Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –

Good Clinical Practice GCP overview

Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.

IFAH-Europe (International Federation for Animal Health Europe) is the federation representing manufacturers of veterinary medicines, vaccines and other.

Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958 (FFDCA) Katie Buhai Period 3.

REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,

The Accelerating Pace of Medical Development and Challenges in Evaluating Benefit and Risk Alasdair Breckenridge Medicines and Healthcare products Regulatory.

3/3/2010Handshake to Success Crescent Healthcare is a premier infusion company founded in 1992 to provide home infusion services to patients with chronic.

© 2009 Cengage Learning. All Rights Reserved. Clinical Research.

EU Council Directive on Traditional Herbal Medicinal Products Dr. Dairine Dempsey IRISH MEDICINES BOARD for IHTA AGM 23 rd April 2003.

Food and Drug Administration & Outbreaks

1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.

Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.

Anthony Serracino Inglott Chairman of the Malta Medicines Authority

Community Health. Something to think about...  What are the different agencies that provide for the community locally, nationally, and globally?

 Food and Drug Administration The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary.

Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Public hearings.

Istanbul April 2011 Dr Joe Collins MVB PhD CBiol FSB MRCVS CertEP CertVR VMPs: - Availability - MUMS - Cascade.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.

China EU Pharmaceutical Forum

1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.

Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.

M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.

Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.

 The Work of Civil Society in the Field of HIV Prevention Brussels, 23 February 2011 The Work of European AIDS Treatment Group (EATG) 1.

ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.

POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION

My Experiences as an FDA Statistician

A capacity building programme for patient representatives

Efficacy and Safety of Medicines

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

LITERATURE REVIEW As the pharmaceutical industries throughout the world are moving ahead towards becoming more and more competitive, regulatory agencies.

Regulation EU 536/2014 on clinical trials

ICH-GCP Avinash Kondawar M. Pharm Lead CRA

Case Studies in Big Data and Analysis

Food and drug administration

Government Regulations to Control Diseases

REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.

American Society for Quality Region 5 Quality Conference

Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.

The importance of dialogue between regulators

Beyond Academia.

Government Regulations for Disease Prevention

Clinical Research Association TURKEY

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Research, Experimentation, & Clinical Trials

Saudi Arabia: Veterinary Pharmaceutical Legislations &

Presentation transcript:

Prof. A. De Wever SAFETY, EFFICACY, QUALITY AND RISK/BENFIT RATIO Source : Marc Czarka

Prof. A. De Wever  Two regulatory bodies  one to regulate the public financing  one to regulate the safety, efficacy, quality and risk/benefit ratio Why laws and regulations ?

Prof. A. De Wever TIMELINES Pure Food and Drug Act 1906 Numerous health scandals 1938 Food, Drug and Cosmetic Act Sulfanilamide syrop scandal SAFETY 1927 FDA est. Why laws and regulations ?

Prof. A. De Wever TIMELINES Creation of nat’l regulatory bodies in Europe 1961 Thalidomide Nuremberg Code 1949 WWII “medical” experiments Kefauver- Harris Amendments ’s Creation of Japanese regulatory body SAFETY AND EFFICACY PROTECTION OF HUMAN SUBJECTS Why laws and regulations ?

Prof. A. De Wever Why laws and regulations ? TIMELINES Towards some harmonisation within the EEC EEC directive 65/65/EC Declaration of Helsinki ICH 1990 Towards more global harmonisation 1981 GCP/FDA PROTECTION OF HUMAN SUBJECTS

Prof. A. De Wever TIMELINES European directive 2002/… on clinical trials 2002 Towards more harmonisation within the EU What’s next? ?1995 Creation of the EMEA Towards more harmonisation within the EU PROTECTION OF HUMAN SUBJECTS Why laws and regulations ?

Prof. A. De Wever FDA's Mission Statement The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. Why laws and regulations ?

Prof. A. De Wever FDA's Mission Statement The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health. accessed on 18APR accessed on 18APR2004 Why laws and regulations ?

Prof. A. De Wever EMEA Mission Statement To contribute to the protection and promotion of public and animal health by :  Mobilising scientific resources from throughout the European Union to provide high quality evaluation of medicinal products, to advise on research and development programmes and to provide useful and clear information to users and health professionals. Why laws and regulations ?

Prof. A. De Wever EMEA Mission Statement  Developing efficient and transparent procedures to allow timely access by users to innovative medicines through a single European marketing authorisation.  Controlling the safety of medicines for humans and animals, in particular through a pharmacovigilance network and the establishment of safe limits for residues in food-producing animals. accessed on 18APR2004 Why laws and regulations ?

The healthcare professionals magazine 6x/year - FR/NL readers —————————— Hot topics seminars driven by reknown opinion leaders